Knowledge of HbA1c and LDL-C treatment goals, subjective level of disease-related information and information needs in patients with atherosclerotic cardiovascular disease.
glycated
hemoglobin (HbA1c)
information needs
low-density lipoprotein cholesterol (LDL cholesterol)
patient information
patient knowledge
treatment goals
Journal
Clinical cardiology
ISSN: 1932-8737
Titre abrégé: Clin Cardiol
Pays: United States
ID NLM: 7903272
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
revised:
28
10
2022
received:
01
06
2022
accepted:
30
10
2022
pubmed:
1
12
2022
medline:
18
2
2023
entrez:
30
11
2022
Statut:
ppublish
Résumé
Risk factor control of diabetes mellitus (DM) and especially dyslipidemia remains unsatisfactory in patients with atherosclerotic cardiovascular disease (ASCVD). We aimed to analyze the knowledge of low-density lipoprotein cholesterol (LDL-C) and glycated hemoglobin (HbA1c) treatment goals, subjective level of information, and information needs in very high-risk patients with ASCVD. ASCVD patients (n = 210; 75 ± 9 years; 71.4% male; 89.5% coronary disease) with DM (96.7% type 2) completed a questionnaire assessing knowledge of HbA1c and LDL-C treatment goals and subjective level of information and information needs on disease-related topics of DM and ASCVD. Serum LDL-C and HbA1c were measured. HbA1c goal (<7.0% in 60.6%) was attained more frequently than LDL-C goal (<70 mg/dl in 39.9%; p < .01). Significantly more participants named the correct goal for HbA1c compared to LDL-C (52.9% vs. 2.4%; p < .01). Subjective levels of information were higher and information needs were lower for DM than for ASCVD (p < .01 for all topics). No associations of knowledge of treatment goals and level of information with the attainment of treatment goals for HbA1c and LDL-C were found. However, in multivariate regression, higher levels of education were associated with knowledge of treatment goals (HbA1c: odds ratio [OR] 1.32, 95% confidence interval [CI] 1.01-1.72, p = .04; LDL-C: OR 2.32, 95% CI 1.07-5.03; p = .03). In very high-risk patients with ASCVD, a deficit of knowledge of treatment goals to control dyslipidemia exists when compared to DM, patients felt significantly better informed for topics of DM than for ASCVD and display higher information needs for topics of ASCVD.
Sections du résumé
BACKGROUND/HYPOTHESIS
OBJECTIVE
Risk factor control of diabetes mellitus (DM) and especially dyslipidemia remains unsatisfactory in patients with atherosclerotic cardiovascular disease (ASCVD). We aimed to analyze the knowledge of low-density lipoprotein cholesterol (LDL-C) and glycated hemoglobin (HbA1c) treatment goals, subjective level of information, and information needs in very high-risk patients with ASCVD.
METHODS
METHODS
ASCVD patients (n = 210; 75 ± 9 years; 71.4% male; 89.5% coronary disease) with DM (96.7% type 2) completed a questionnaire assessing knowledge of HbA1c and LDL-C treatment goals and subjective level of information and information needs on disease-related topics of DM and ASCVD. Serum LDL-C and HbA1c were measured.
RESULTS
RESULTS
HbA1c goal (<7.0% in 60.6%) was attained more frequently than LDL-C goal (<70 mg/dl in 39.9%; p < .01). Significantly more participants named the correct goal for HbA1c compared to LDL-C (52.9% vs. 2.4%; p < .01). Subjective levels of information were higher and information needs were lower for DM than for ASCVD (p < .01 for all topics). No associations of knowledge of treatment goals and level of information with the attainment of treatment goals for HbA1c and LDL-C were found. However, in multivariate regression, higher levels of education were associated with knowledge of treatment goals (HbA1c: odds ratio [OR] 1.32, 95% confidence interval [CI] 1.01-1.72, p = .04; LDL-C: OR 2.32, 95% CI 1.07-5.03; p = .03).
CONCLUSION
CONCLUSIONS
In very high-risk patients with ASCVD, a deficit of knowledge of treatment goals to control dyslipidemia exists when compared to DM, patients felt significantly better informed for topics of DM than for ASCVD and display higher information needs for topics of ASCVD.
Identifiants
pubmed: 36448416
doi: 10.1002/clc.23948
pmc: PMC9933116
doi:
Substances chimiques
Cholesterol, LDL
0
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Glycated Hemoglobin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
223-231Subventions
Organisme : Forschungskommission of the Medical Faculty of the Heinrich-Heine-University Düsseldorf, Germany
ID : Clinician Scientist Track to GW (No. 2018-32)
Informations de copyright
© 2022 The Authors. Clinical Cardiology published by Wiley Periodicals LLC.
Références
Eur Heart J. 2012 Nov;33(22):2865-72
pubmed: 22843446
Indian J Endocrinol Metab. 2021 May-Jun;25(3):206-210
pubmed: 34760675
Eur Heart J. 2016 Aug 1;37(29):2315-2381
pubmed: 27222591
Eur J Prev Cardiol. 2018 Jul;25(10):1087-1094
pubmed: 29771156
Pharm Pract (Granada). 2006 Oct-Dec;4(4):183
pubmed: 28603577
Patient Educ Couns. 2010 Mar;78(3):316-28
pubmed: 20005067
Prim Care Diabetes. 2016 Aug;10(4):287-92
pubmed: 26777538
Patient Educ Couns. 2010 Aug;80(2):227-32
pubmed: 20036098
Eur J Prev Cardiol. 2022 Feb 19;29(1):5-115
pubmed: 34558602
Eur Heart J. 2020 Jan 1;41(1):111-188
pubmed: 31504418
Dtsch Arztebl Int. 2017 Jan 27;114(4):53-60
pubmed: 28211318
Diabetes Care. 2021 Jan;44(Suppl 1):S111-S124
pubmed: 33298420
Eur J Cardiovasc Nurs. 2004 Dec;3(4):321-30
pubmed: 15572021
Health Expect. 2011 Mar;14(1):92-104
pubmed: 20550592
Eur J Prev Cardiol. 2019 May;26(8):824-835
pubmed: 30739508
Prev Cardiol. 2005 Winter;8(1):11-7
pubmed: 15722689
Eur J Prev Cardiol. 2021 Sep 20;28(11):1279-1289
pubmed: 33580789
Diabetes Care. 2019 Nov;42(11):2136-2142
pubmed: 31530661
Patient Prefer Adherence. 2019 Nov 29;13:2017-2027
pubmed: 31819383
Z Evid Fortbild Qual Gesundhwes. 2016;110-111:85-92
pubmed: 26875040
Clin Cardiol. 2023 Feb;46(2):223-231
pubmed: 36448416
BMC Health Serv Res. 2015 Sep 23;15:407
pubmed: 26399759
Diabetes Care. 2007 Jun;30(6):1587-9
pubmed: 17372160
Prim Care Diabetes. 2017 Oct;11(5):414-420
pubmed: 28684227
Eur J Prev Cardiol. 2020 Jun 03;:
pubmed: 33611449
BMJ Open. 2018 Oct 31;8(10):e017895
pubmed: 30385437
Eur J Prev Cardiol. 2016 Dec;23(18):2007-2018
pubmed: 27638542
Eur J Prev Cardiol. 2017 Jul;24(10):1032-1042
pubmed: 28406328
Eur Heart J. 2016 Oct 14;37(39):2999-3058
pubmed: 27567407
J Am Coll Cardiol. 2013 Apr 16;61(15):1607-15
pubmed: 23500281
J Am Heart Assoc. 2021 Aug 17;10(16):e020893
pubmed: 34369165
J Glob Health. 2017 Dec;7(2):020702
pubmed: 29057073
Health Qual Life Outcomes. 2021 Jan 6;19(1):3
pubmed: 33407579
Health Res Policy Syst. 2020 Jun 29;18(1):74
pubmed: 32600417
Cardiovasc Diabetol. 2015 Oct 01;14:133
pubmed: 26427624
BMC Public Health. 2020 Dec 10;20(1):1901
pubmed: 33302924
PLoS One. 2014 Sep 17;9(9):e107828
pubmed: 25229640